Cross-talk between the airway epithelium and activated immune cells defines severity in COVID-19
By
Robert Lorenz Chua,
Soeren Lukassen,
Saskia Trump,
Bianca P Hennig,
Daniel Wendisch,
Fabian Pott,
Olivia Debnath,
Loreen Thürmann,
Florian Kurth,
Julia Kazmierski,
Bernd Timmermann,
Sven Twardziok,
Stefan Schneider,
Felix Machleidt,
Holger Müller-Redetzky,
Alexander Krannich,
Sein Schmidt,
Felix Balzer,
Johannes Liebig,
Jennifer Loske,
Jürgen Eils,
Naveed Ishaque,
Christof von Kalle,
Andreas Hocke,
Martin Witzenrath,
Christine Goffinet,
Christian Drosten,
Sven Laudi,
Irina Lehmann,
Christian Conrad,
Leif-Erik Sander,
Roland Eils
Posted 05 May 2020
medRxiv DOI: 10.1101/2020.04.29.20084327
The clinical course of COVID-19 is highly variable, however, underlying host factors and determinants of severe disease are still unknown. Based on single-cell transcriptomes of nasopharyngeal and bronchial samples from clinically well-characterized patients presenting with moderate and critical severities, we reveal the different types and states of airway epithelial cells that are vulnerable for SARS-CoV-2 infection. In COVID-19 patients, we observed a two- to threefold increase of cells expressing the SARS-CoV-2 entry receptor ACE2 within the airway epithelial cell compartment. ACE2 is upregulated in epithelial cells through Interferon signals by immune cells suggesting that the viral defense system may increase the number of potentially susceptible cells in the respiratory epithelium. Infected epithelial cells recruit and activate immune cells by chemokine signaling. Recruited T lymphocytes and inflammatory macrophages were hyperactivated and showed a strong interaction with epithelial cells. In critical patients, increased expression of CCL2, CCL3, CCL5, CXCL9, CXCL10, IL8, IL1B and TNF in macrophages was identified as a likely cause of a hyperinflammatory lung pathology. Moreover, we observed exacerbated epithelial cell death, likely leading to lung injury and respiratory failure in fatal cases. Our study provides novel insights into the pathophysiology of COVID-19 and suggests an immunomodulatory therapy along the CCL2, CCL3/CCR1 axis as promising option to prevent and treat critical course of COVID-19.
Download data
- Downloaded 5,346 times
- Download rankings, all-time:
- Site-wide: 1,817
- In infectious diseases: 434
- Year to date:
- Site-wide: 7,370
- Since beginning of last month:
- Site-wide: 9,283
Altmetric data
Downloads over time
Distribution of downloads per paper, site-wide
PanLingua
News
- 27 Nov 2020: The website and API now include results pulled from medRxiv as well as bioRxiv.
- 18 Dec 2019: We're pleased to announce PanLingua, a new tool that enables you to search for machine-translated bioRxiv preprints using more than 100 different languages.
- 21 May 2019: PLOS Biology has published a community page about Rxivist.org and its design.
- 10 May 2019: The paper analyzing the Rxivist dataset has been published at eLife.
- 1 Mar 2019: We now have summary statistics about bioRxiv downloads and submissions.
- 8 Feb 2019: Data from Altmetric is now available on the Rxivist details page for every preprint. Look for the "donut" under the download metrics.
- 30 Jan 2019: preLights has featured the Rxivist preprint and written about our findings.
- 22 Jan 2019: Nature just published an article about Rxivist and our data.
- 13 Jan 2019: The Rxivist preprint is live!